Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

IMPORTANCE: Chimeric antigen receptor (CAR) T cell therapies are approved as a third-line or later therapy for several hematological malignant neoplasms. Recently, randomized clinical trials have investigated their efficacy as a second-line treatment in high-risk relapsed or refractory diffuse large...

Descripción completa

Detalles Bibliográficos
Autores principales: Choe, Jee H., Abdel-Azim, Hisham, Padula, William V., Abou-el-Enein, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856352/
https://www.ncbi.nlm.nih.gov/pubmed/36520440
http://dx.doi.org/10.1001/jamanetworkopen.2022.45956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856352/
https://www.ncbi.nlm.nih.gov/pubmed/36520440
http://dx.doi.org/10.1001/jamanetworkopen.2022.45956

Ejemplares similares